Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (2977)	11/24/1997 11:27:00 PM
From: Izzy	Read Replies (2) of 6136

The problem is that the article was published in the WSJ, page C7, and specifically mentions AGPH with reference to the company being dependent on one drug only. "If something happens to the product, the stock can go back down" [which it actually did today]. However, this article is pure bunk when it comes to AGPH. In fact, the whole article, which mentioned unsuccesssful biotechs, is very slanted and rather stupid, IMO. Baloney to the author! It would be nice if Bill K. (or anyone) would rebut this article's falsities. Uninformed investors are being mislead.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next